Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry. (PubMed, RMD Open) - Sep 26, 2026 - "The 52-week clinical effectiveness of the RTX-based, MMF-based and IVCY-based strategies for active lupus nephritis did not differ significantly. Different within-strategy immunophenotypic patterns were observed, but between-strategy differences were not confirmed. Comprehensive immunophenotyping may help characterise immune dynamics and support future response stratification and precision medicine for lupus nephritis."
Journal • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Hidenori Sakai; Hiroaki Tanaka; Ippei Miyagawa; Katsuhide Kusaka; Masanobu Ueno; Ryuichiro Kanda; Satoshi Kubo; Shingo Nakayamada; Yasuyuki Todoroki; Yoshiya Tanaka; Yusuke Miyazaki; Yuya Fujita
|